The EYERISING Study
Key facts
- Who runs it
- University of Wisconsin, Madison
- Where
- Madison, United StatesSee the siteAlso in 1 other country, 1 site
- Trial code
- Status
- Not yet recruiting
- People taking part
- 333 people, planned
- Starts
- Dec 2026
- Expected to end
- May 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Repeated Low-Level Red Light (RLRL) therapy
- Placebo Device
- Record updated
- 5 November 2026
Who can take part
- Age
- 6 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Age ≥ 6 and ≤ 12 (at screening)
- Myopia: Cycloplegic SER -1.0 to -7.0 D
- Astigmatism: < 1.5 D
- Anisometropia: < 1.5 D
- Informed parental consent
- Consistent access to wireless internet
Who cannot take part
- A subject who is born female and who is currently menstruating or has begun menstruation (menarche); Ophthalmic diseases, conditions, or syndromes other than refractive errors; Previous use of treatment for myopia control (e.g., defocusing lenses or contact lenses, orthokeratology, atropine, and pirenzepine); Any previous ocular surgery; Systemic diseases (e.g., endocrine, cardiac diseases) and developmental anomalies; Inability to attend regular follow up visits; Participants with any symptom, disease, or other condition that, in the opinion of the investigators, may affect the effectiveness of the investigational treatment and/or the ability of the participant to complete study activities
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 6 and 12 years old?
Where in United States
Also in 1 other country, 1 site
- University of Wisconsin - MadisonMadison, United StatesContact: Angie AdlerNot yet recruiting
About the trial
What the trial wants to find out
The purpose of this clinical trial is to see if and how well Repeated Low-Level Red Light (RLRL) therapy works to control myopia over 12 months. The main question it aims to answer is:
Read full original descriptionShow less
* Can RLRL therapy help slow down the worsening of myopia?
Participants will use a red-light therapy investigational device at home, 5 days a week for 12 months.
The 2 groups in the trial
- Red light therapyTreatment being tested
Participants will receive red light therapy
Treatment: Repeated Low-Level Red Light (RLRL) therapy
- PlaceboPlacebo, for comparison
Participants will receive placebo therapy
Treatment: Placebo Device
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Repeated Low-level Red Light for Myopia Progression Study: An International, Multicenter, Multiethnic, Randomized Controlled Trial, IPOSC Study
- Criteria questions
- Built from NCT07909720, who can take part
- Record updated
- 5 November 2026